| Scrip Code | 500087 |
|---|---|
| NSE Symbol | CIPLA |
| MSEI Symbol | NOTLISTED |
| ISIN | INE059A01026 |
| Name of company | CIPLA LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 13-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 31-03-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceutical and related products |
| Start date and time of board meeting | 13-05-2026 09:45:00 |
| End date and time of board meeting | 13-05-2026 13:00:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 6,54,120.00 | 28,16,259.00 | |
| Other income | 14,816.00 | 88,201.00 | |
| Total income | 6,68,936.00 | 29,04,460.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 1,38,215.00 | 5,84,162.00 |
| (b) | Purchases of stock-in-trade | 1,28,473.00 | 4,45,137.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (41,820.00) | (74,388.00) |
| (d) | Employee benefit expense | 1,41,425.00 | 5,36,633.00 |
| (e) | Finance costs | 1,313.00 | 5,439.00 |
| (f) | Depreciation, depletion and amortisation expense | 38,292.00 | 1,21,098.00 |
| (f) | Other Expenses | ||
| 1 | Impairment of investment in associates | 4,202.00 | 4,202.00 |
| 2 | Other expenses | 1,88,130.00 | 7,32,223.00 |
| Total other expenses | 1,92,332.00 | 7,36,425.00 | |
| Total expenses | 5,98,230.00 | 23,54,506.00 | |
| 3 | Total profit before exceptional items and tax | 70,706.00 | 5,49,954.00 |
| 4 | Exceptional items | 0.00 | (27,591.00) |
| 5 | Total profit before tax | 70,706.00 | 5,22,363.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 28,217.00 | 1,44,095.00 |
| 8 | Deferred tax | (12,522.00) | (8,711.00) |
| 9 | Total tax expenses | 15,695.00 | 1,35,384.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 55,011.00 | 3,86,979.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | (760.00) | (805.00) |
| 16 | Total profit (loss) for period | 54,251.00 | 3,86,174.00 |
| 17 | Other comprehensive income net of taxes | 13,579.00 | 68,774.00 |
| 18 | Total Comprehensive Income for the period | 67,830.00 | 4,54,948.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 55,464.00 | 3,87,923.00 | |
| Total profit or loss, attributable to non-controlling interests | (1,213.00) | (1,749.00) | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 69,207.00 | 4,56,792.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | (1,377.00) | (1,844.00) | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 16,156.00 | 16,156.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 34,27,039.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 6.87 | 48.03 | |
| Diluted earnings (loss) per share from continuing operations | 6.86 | 48 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 6.87 | 48.03 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 6.86 | 48 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Not Applicable |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 31-03-2026 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 6,03,980.00 | ||
| Capital work-in-progress | 1,58,628.00 | ||
| Investment property | 0.00 | ||
| Goodwill | 3,75,442.00 | ||
| Other intangible assets | 2,64,014.00 | ||
| Intangible assets under development | 45,594.00 | ||
| Biological assets other than bearer plants | 0.00 | ||
| Investments accounted for using equity method | 11,175.00 | ||
| Non-current financial assets | |||
| Non-current investments | 43,224.00 | ||
| Trade receivables, non-current | 0.00 | ||
| Loans, non-current | 276.00 | ||
| Other non-current financial assets | |||
| 1 | Other financial assets | 1,19,410.00 | |
| Total of other non-current financial assets | 1,19,410.00 | ||
| Total non-current financial assets | 1,62,910.00 | ||
| Deferred tax assets (net) | 90,102.00 | ||
| Other non-current assets | |||
| 1 | Non-current tax assets (net) | 57,328.00 | |
| 2 | Other non-current assets | 65,722.00 | |
| Total of other non-current assets | 1,23,050.00 | ||
| Total non-current assets | 18,34,895.00 | ||
| 2 | Current assets | ||
| Inventories | 6,59,672.00 | ||
| Current financial asset | |||
| Current investments | 7,67,942.00 | ||
| Trade receivables, current | 5,62,005.00 | ||
| Cash and cash equivalents | 1,01,822.00 | ||
| Bank balance other than cash and cash equivalents | 28,920.00 | ||
| Loans, current | 2,312.00 | ||
| Other current financial assets | |||
| Total of other current financial assets | 1,46,023.00 | ||
| Total current financial assets | 16,09,024.00 | ||
| Current tax assets (net) | 0.00 | ||
| Other current assets | |||
| 1 | Other current assets | 1,45,890.00 | |
| Total of other current assets | 1,45,890.00 | ||
| Total current assets | 24,14,586.00 | ||
| 3 | Non-current assets classified as held for sale | 117.00 | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | ||
| Total assets | 42,49,598.00 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 16,156.00 | ||
| Other equity | 34,27,039.00 | ||
| Total equity attributable to owners of parent | 34,43,195.00 | ||
| Non controlling interest | 8,829.00 | ||
| Total equity | 34,52,024.00 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 11,747.00 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | ||
| Total Trade payable | 0.00 | ||
| Other non-current financial liabilities | |||
| 1 | Lease liabilities | 26,448.00 | |
| 2 | Other financial liabilities | 22,040.00 | |
| Total of other non-current financial liabilities | 48,488.00 | ||
| Total non-current financial liabilities | 60,235.00 | ||
| Provisions, non-current | 15,756.00 | ||
| Deferred tax liabilities (net) | 15,327.00 | ||
| Deferred government grants, Non-current | 0.00 | ||
| Other non-current liabilities | |||
| 1 | Other non-current liabilities | 4,897.00 | |
| Total of other non-current liabilities | 4,897.00 | ||
| Total non-current liabilities | 96,215.00 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 14,050.00 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 21,518.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 3,01,472.00 | ||
| Total Trade payable | 3,22,990.00 | ||
| Other current financial liabilities | |||
| 1 | Lease Liabilities | 9,132.00 | |
| 2 | Other financial liabilities | 98,677.00 | |
| Total of other current financial liabilities | 1,07,809.00 | ||
| Total current financial liabilities | 4,44,849.00 | ||
| Other current liabilities | 30,050.00 | ||
| 1 | Other current liabilities | 30,050.00 | |
| Total of other current liabilities | 30,050.00 | ||
| Provisions, current | 2,25,915.00 | ||
| Current tax liabilities (Net) | 545.00 | ||
| Deferred government grants, Current | |||
| Total current liabilities | 7,01,359.00 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | ||
| 4 | Regulatory deferral account credit balances and related deferred tax liability | ||
| Total liabilities | 7,97,574.00 | ||
| Total equity and liabilites | 42,49,598.00 | ||
| Disclosure of notes on assets and liabilities | Textual Information(1) | ||
| Textual Information(1) | 1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of INR 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July, 2025 the Company has voluntarily deposited with the NPPA an additional amount of INR 27.07 Crores towards the principal against certain demand notices. The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to INR 2,011 Crores with the principal of INR 863 Crores and interest of INR 1,148 Crores. The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively “Okasa), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to INR 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla’s subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon’ble Bombay HC. The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa. 3. The paid-up equity share capital stands increased to INR 161.56 Crores (80,77,82,631 equity shares of face value INR 2 each) upon allotment of 8,384 equity shares and 2,449 equity shares of INR 2 each pursuant to ESOS 2013-A and “Cipla ESAR Scheme 2021” respectively during the quarter ended 31st March, 2026. 4. Effective 21st November,2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by INR 275.91 Crores primarily arising due to change in the definition of “wages” for employees and contract labours. Considering the materiality and non-recurring nature of this impact, the Group has presented such incremental impact under “Exceptional Item” in the consolidated financial results for the quarter ended 31st December, 2025 and year ended 31st March, 2026. 5. The Company has entered into definitive agreement to acquire 100% stake in Inzpera Heathscience Limited (Inzpera) for a purchase consideration of INR 110.65 Crores for acquisition of equity shares and non-convertible redeemable preference shares. The transaction has been completed on 4th December, 2025, upon fulfilment of all closing conditions. The fair value of assets and liabilities acquired have been determined and accounted for in accordance with Ind AS 103 ‘Business Combinations’ and total consideration has been allocated based on purchase price allocation carried out by external valuer as under: Particulars INR in Crores Consideration transferred (a) 110.65 Net identifiable assets acquired (b) (43.95) Goodwill (a-b) 66.70 6. The audited standalone financial results for the quarter ended 31st March, 2026 are available on the Company’s website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. 7. The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 8. The Board of Directors of the Company at its meeting held on 13th May, 2026 has recommended a final dividend of INR 13/- per equity share (face value of INR 2 each) for the financial year ended 31st March, 2026. The dividend is subject to approval of the shareholders at the ensuing annual general meeting of the Company. 9. Operating segment information is presented in a manner consistent with the internal reporting reviewed by the Group’s Chief Operating Decision Maker (“CODM”) for the purpose of allocating resources and assessing performance. The CODM of the Group is the Chief Executive Officer, who is responsible for making strategic decisions. During the quarter ended 31st March 2026, the Group reassessed its operating segments consequent to a change in the CODM. Based on this reassessment, the Group has determined that it operates as a single operating segment, namely Pharmaceutical and related products. Accordingly, the comparative information for the previous year has been restated, wherever necessary, to reflect the Group as operating under a single reportable segment, in accordance with Ind AS 108 – Operating Segments. 10. During the quarter and year ended 31st March 2026, the group has recorded an impairment of INR 42.02 Crores in the financial results in respect of associates, on account of change in certain business conditions and market dynamics. 11. The Board in its meeting held on 19th March 2026, has approved the scheme of amalgamation between Cipla Limited (“Transferee Company”) and its wholly owned subsidiary company Inzpera Healthsciences Limited (“Transferor Company”). The Scheme of Amalgamation is subject to necessary approvals required under the Companies Act, 2013, including approval of the Hon’ble National Company Law Tribunal, Mumbai. The Company is in the process of filing the Scheme with the authorities. 12. The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current year/period. 13. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 13th May, 2026. These results have been subjected to audit by statutory auditors who have expressed an unqualified opinion. |
|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | Not Applicable |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit or loss | (17,796.00) | (18,893.00) |
| Total Amount of items that will not be reclassified to profit and loss | (17,796.00) | (18,893.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 69.00 | (207.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified to profit or loss | 30,197.00 | 82,814.00 |
| Total Amount of items that will be reclassified to profit and loss | 30,197.00 | 82,814.00 | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | (1,247.00) | (4,646.00) |
| 5 | Total Other comprehensive income | 13,579.00 | 68,774.00 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Consolidated | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 5,22,363.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 5,439.00 | |||||
| Adjustments for decrease (increase) in inventories | (64,239.00) | |||||
| Adjustments for decrease (increase) in trade receivables, current | 46,529.00 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (70,118.00) | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | 25,258.00 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 40,048.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 1,25,300.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 0.00 | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (10,330.00) | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 22,857.00 | |||||
| Adjustments for share-based payments | 5,905.00 | |||||
| Adjustments for fair value losses (gains) | (12,814.00) | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (38,353.00) | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | 491.00 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 30,259.00 | |||||
| Net cash flows from (used in) operations | 5,52,622.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 1,58,620.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 3,94,002.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 11,065.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 1,563.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 2,356.00 | |||||
| Purchase of property, plant and equipment | 1,59,933.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 4,405.00 | |||||
| Purchase of intangible assets | 1,47,998.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 1,737.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 22,292.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 60,630.00 | |||||
| Net cash flows from (used in) investing activities | (2,32,613.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 4.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 18,778.00 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 10,782.00 | |||||
| Dividends paid | 1,29,240.00 | |||||
| Interest paid | 3,703.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 1,578.00 | |||||
| Net cash flows from (used in) financing activities | (1,23,365.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 38,024.00 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 9,250.00 | |||||
| Net increase (decrease) in cash and cash equivalents | 47,274.00 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 54,265.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 1,01,539.00 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Walker Chandiok & Co LLP | Yes | 31-05-2028 | ||
|---|---|---|---|---|---|